LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
ELI LILLY & Co
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1240.34−16.69 (-1.33%)
Close on Oct 19, 2026
- Market cap
- $1.11T
- P/E (TTM)
- 41.6
- Dividend yield
- 0.50%
ELI LILLY & Co revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product revenue | $21.40B | $18.45B | $18.30B | $16.33B | $14.73B | $11.60B | $12.03B | $10.57B | $10.35B | $7.80B | $8.29B | $7.31B | 93.2% | +45.3% |
| Cardiometabolic Health | $18.35B | $15.76B | – | $13.18B | $11.34B | $9.21B | – | $7.41B | $7.51B | $5.49B | – | $4.72B | 79.9% | +61.8% |
| Mounjaro | $9.94B | $8.66B | – | $6.52B | $5.20B | $3.84B | – | $3.11B | $3.09B | $1.81B | – | $1.41B | 43.3% | +91.2% |
| Zepbound | $4.93B | $4.16B | – | $3.59B | $3.38B | $2.31B | – | $1.26B | $1.24B | $517.40M | – | $0 | 21.5% | +45.8% |
| Oncology | $2.57B | $2.27B | – | $2.41B | $2.41B | $1.95B | – | $2.23B | $2.16B | $1.81B | – | $1.75B | 11.2% | +6.5% |
| Collaboration and other revenue | $1.57B | $1.35B | $991.70M | $1.27B | $832.00M | $1.13B | $1.51B | $867.50M | $947.90M | $971.50M | $1.06B | $2.19B | 6.8% | +88.8% |
| Verzenio | $1.47B | $1.30B | – | $1.47B | $1.49B | $1.16B | – | $1.37B | $1.33B | $1.05B | – | $1.04B | 6.4% | -1.0% |
| Immunology | $1.42B | $1.20B | – | $1.36B | $1.26B | $1.09B | – | $1.19B | $1.08B | $834.00M | – | $986.90M | 6.2% | +12.8% |
| Jardiance | $1.23B | $1.11B | $768.60M | $959.00M | $690.00M | $1.01B | $1.20B | $686.40M | $769.60M | $686.50M | $798.40M | $700.80M | 5.4% | +78.6% |
| Trulicity | $1.22B | $919.00M | – | $1.05B | $1.09B | $1.10B | – | $1.30B | $1.25B | $1.46B | – | $1.67B | 5.3% | +11.6% |
| Other oncology | $1.10B | $966.00M | – | $937.40M | $924.00M | $789.00M | – | $862.50M | $826.80M | $759.70M | – | $213.80M | 4.8% | +18.6% |
| Other cardiometabolic health | $1.03B | $905.00M | – | $1.06B | $980.00M | $945.00M | – | $1.05B | $1.17B | $1.03B | – | $141.90M | 4.5% | +5.2% |
| Taltz | $856.00M | $733.00M | – | $901.50M | $848.00M | $762.00M | – | $879.60M | $824.70M | $604.10M | – | $744.20M | 3.7% | +0.9% |
| Other immunology | $561.00M | $470.00M | – | $460.90M | $408.00M | $326.00M | – | $306.10M | $257.70M | $229.90M | – | $11.40M | 2.4% | +37.5% |
| Neuroscience | $429.00M | $382.00M | – | $315.70M | $344.00M | $272.00M | – | $351.80M | $339.50M | $389.10M | – | $1.77B | 1.9% | +24.7% |
| Other | $205.00M | $187.00M | – | – | $202.00M | $213.00M | – | – | – | – | – | – | 0.9% | +1.5% |
| Erbitux | – | – | – | – | – | – | – | $152.00M | $155.80M | $144.60M | – | $153.90M | – | – |
| Trajenta | – | – | – | – | – | – | – | $91.70M | $76.60M | $88.90M | $102.20M | $95.20M | – | – |
| Basaglar | – | – | – | – | – | – | $176.90M | $161.60M | $180.80M | $157.60M | $185.20M | $179.60M | – | – |
| Collaboration and other revenue associated with prior period transfers of intellectual property | – | – | – | – | – | – | – | – | – | – | $104.80M | $31.30M | – | – |
| Alimta | – | – | – | – | – | – | – | – | – | – | – | $53.50M | – | – |
| Cialis | – | – | – | – | – | – | – | $91.50M | $87.70M | $139.30M | – | $86.80M | – | – |
| Cyramza | – | – | – | – | – | – | – | $236.00M | $248.90M | $229.90M | – | $224.10M | – | – |
| Emgality | – | – | – | – | – | – | – | $202.90M | $192.00M | $225.70M | – | $168.50M | – | – |
| Forteo | – | – | – | – | – | – | – | $118.10M | $69.90M | $61.30M | – | $146.40M | – | – |
| Humalog | – | – | – | – | – | – | – | $534.60M | $631.60M | $538.70M | – | $395.40M | – | – |
| Humulin | – | – | – | – | – | – | – | $207.10M | $223.60M | $206.20M | – | $206.70M | – | – |
| Other neuroscience | – | – | – | – | – | – | – | $117.20M | $147.50M | $163.40M | – | $118.20M | – | – |
| Other | – | – | – | – | – | – | – | $53.20M | $50.00M | $41.30M | – | $42.90M | – | – |
| Other | – | – | – | $337.20M | $201.50M | $212.90M | – | $262.80M | $207.60M | $241.90M | – | $276.10M | – | – |
| Zyprexa | – | – | – | – | – | – | – | $31.70M | – | – | – | $1.48B | – | – |
| Olumiant | – | – | – | – | – | – | $261.50M | $250.80M | $227.70M | $217.40M | $243.40M | $231.40M | – | – |
| Other diabetes | – | – | – | – | – | – | – | – | – | – | – | $141.90M | – | – |
| Diabetes | – | – | – | – | – | – | – | – | – | – | – | $4.72B | – | – |
| COVID-19 antibodies | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Baqsimi | – | – | – | – | – | – | – | $13.40M | $12.40M | – | – | $13.10M | – | – |
| Tyvyt | – | – | – | – | – | – | – | $150.20M | $123.00M | $116.70M | – | $115.10M | – | – |
| Diabetes and obesity | – | – | – | – | – | – | – | – | – | $5.49B | – | – | – | – |
| Other diabetes and obesity | – | – | – | – | – | – | – | – | – | $123.80M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $14.41B | $12.12B | $12.88B | $11.30B | $10.81B | $8.49B | $9.03B | $7.81B | $7.84B | $5.69B | $6.46B | $5.37B | 62.7% | +33.3% |
| Outside U.S. | $8.56B | $7.68B | $6.41B | $6.30B | $4.74B | $4.24B | $4.50B | $3.63B | $3.47B | $3.07B | $2.90B | $4.13B | 37.3% | +80.5% |
| Europe | $4.12B | $3.65B | $3.10B | $3.50B | $2.57B | $2.39B | $2.45B | $1.63B | $1.40B | $1.44B | $1.34B | $2.57B | 17.9% | +59.9% |
| Rest of world | $2.88B | $2.77B | $2.19B | $1.69B | $1.18B | $997.00M | $1.06B | $1.11B | $1.21B | $892.90M | – | – | 12.5% | +143.4% |
| China | $941.00M | $693.00M | $473.20M | $560.40M | $466.00M | $451.00M | $428.80M | $459.90M | $395.10M | $376.20M | $377.40M | $390.80M | 4.1% | +101.9% |
| Japan | $628.00M | $571.00M | $654.80M | $554.70M | $521.00M | $402.00M | $559.30M | $429.10M | $462.70M | $363.90M | $439.40M | $390.80M | 2.7% | +20.5% |
| Other foreign countries | – | – | – | – | – | – | – | $1.11B | $1.21B | $892.90M | $744.40M | $780.30M | – | – |
From the segment and revenue-disaggregation notes of Eli Lilly's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.